- Conditions
- Perforated Eardrum
- Interventions
- Isoflurane Inhalant Product, Sevoflurane inhalant product, Propofol injection, Remifentanil Injection
- Drug
- Lead sponsor
- Our Lady of the Lake Hospital
- Other
- Eligibility
- 0 Years to 100 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Baton Rouge, Louisiana
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2833–2856
of 4,177
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Depression Symptoms
- Interventions
- Creativity Camp
- Other
- Lead sponsor
- University of Minnesota
- Other
- Eligibility
- 12 Years to 17 Years
- Enrollment
- 160 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Prostatectomy
- Interventions
- Radical Prostatectomy, Precision Prostatectomy
- Procedure
- Lead sponsor
- Henry Ford Health System
- Other
- Eligibility
- Male only
- Enrollment
- 160 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Detroit, Michigan
- Conditions
- Contraception
- Interventions
- Interaction with users of IUC and non-IUC users, Interaction with non-IUC users only
- Behavioral
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 630 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Dry Eye
- Interventions
- XG-104, Placebo
- Drug
- Lead sponsor
- Xigen SA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 260 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Andover, Massachusetts
- Conditions
- Stroke, Acute
- Interventions
- Analyze plasma free fatty acid in blood
- Diagnostic Test
- Lead sponsor
- Sanford Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Fargo, North Dakota
- Conditions
- Photoallergy
- Interventions
- SPF 50 Y65 110 (BAY987519), SPF 50 Y51 002 (BAY987519), SPF 15 V27 104 (BAY987519), Sodium chloride [NaCl]
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 56 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Pinellas Park, Florida
- Conditions
- Heart Diseases
- Interventions
- Group 1 (Intervention), Group 2 (Control)
- Behavioral
- Lead sponsor
- Texas A&M University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,420 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2026
- U.S. locations
- 13
- States / cities
- Camden, New York • Canastota, New York • Carthage, New York + 10 more
- Conditions
- Pressure Distribution, Military Litters, Peak Pressure Index, Total Surface Area, Tissue Perfusion
- Interventions
- NATO WELP combination, NATO FIS combination, RAVEN WELP combination, RAVEN FIS combination
- Other
- Lead sponsor
- David Grant U.S. Air Force Medical Center
- Federal
- Eligibility
- 19 Years and older
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Travis Air Force Base, California
- Conditions
- HIV Infections
- Interventions
- HIV-1 Immunogen
- Biological
- Lead sponsor
- The Immune Response Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 54
- States / cities
- Phoenix, Arizona • Irvine, California • Los Angeles, California + 40 more
- Conditions
- Multiple Sclerosis
- Interventions
- mRNA-1195, Placebo
- Biological
- Lead sponsor
- ModernaTX, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 180 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2029
- U.S. locations
- 8
- States / cities
- Boston, Massachusetts • Farmington Hills, Michigan • Ozark, Missouri + 5 more
- Conditions
- Primary Progressive Multiple Sclerosis
- Interventions
- Placebo, Laquinimod
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 25 Years to 55 Years
- Enrollment
- 374 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 15
- States / cities
- Phoenix, Arizona • Newport Beach, California • San Francisco, California + 11 more
- Conditions
- Alzheimer's Disease
- Interventions
- T3D-959, Placebo Comparator
- Drug · Other
- Lead sponsor
- T3D Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 376 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2031
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Infertility
- Interventions
- Preimplantation Genetic Diagnosis (PGD)
- Procedure
- Lead sponsor
- Reprogenetics
- Industry
- Eligibility
- 37 Years to 42 Years · Female only
- Enrollment
- 1,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 4
- States / cities
- Beverly Hills, California • Highland Park, Illinois • Livingston, New Jersey
- Conditions
- Hospitalized Neonates and Infants, Expected to Require Parenteral Nutrition for 28 Days
- Interventions
- Smoflipid 20% (investigational lipid for parenteral nutrition), Intralipid® 20%
- Drug
- Lead sponsor
- Fresenius Kabi
- Industry
- Eligibility
- 0 Weeks and older
- Enrollment
- 204 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2020
- U.S. locations
- 13
- States / cities
- Palo Alto, California • San Diego, California • New Haven, Connecticut + 8 more
- Conditions
- Healthy
- Interventions
- Associative Inference, Probabilistic Inference
- Behavioral
- Lead sponsor
- University of Texas at Austin
- Other
- Eligibility
- 13 Years to 25 Years
- Enrollment
- 142 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2029
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Smoking Cessation
- Interventions
- Spanish-Language Version of the Stop Smoking for Good, NCI-Produced Spanish-language Self-help Booklet
- Behavioral
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1,417 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2020
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- LTP001, Placebo, Standard of Care (SoC)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 40 Years to 100 Years
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Kansas City, Kansas
- Conditions
- Chronic Hepatitis, Hepatitis B
- Interventions
- Clevudine, Adefovir
- Drug
- Lead sponsor
- Pharmasset
- Industry
- Eligibility
- 16 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2007
- U.S. locations
- 63
- States / cities
- Birmingham, Alabama • Anaheim, California • Fresno, California + 36 more
- Conditions
- Osteoarthritis, Knee
- Interventions
- Amniotic Fluid, Saline Placebo
- Other
- Lead sponsor
- MiMedx Group, Inc.
- Industry
- Eligibility
- 30 Years and older
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 4
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Des Plaines, Illinois + 1 more
- Conditions
- Ocular Hypertension, Glaucoma
- Interventions
- AR-13324 Ophthalmic Solution 0.02%, AR-13324 Ophthalmic Solution 0.02% BID, Timolol maleate Ophthalmic Solution 0.5% BID, Placebo
- Drug · Other
- Lead sponsor
- Aerie Pharmaceuticals
- Industry
- Eligibility
- 19 Years to 99 Years
- Enrollment
- 93 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Bedminster, New Jersey
- Conditions
- ALL (Acute B-Lymphoblastic Leukemia), AML (Acute Myeloid Leukemia), MDS (Myelodysplastic Syndrome)
- Interventions
- Not listed
- Lead sponsor
- Miltenyi Biomedicine GmbH
- Industry
- Eligibility
- 1 Year to 66 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Bowel Diseases, Inflammatory
- Interventions
- Celecoxib, Placebo, Ibuprofen plus Omeprazole
- Drug · Other
- Lead sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 408 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2003 – 2004
- U.S. locations
- 12
- States / cities
- Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 8 more
- Conditions
- Macular Degeneration
- Interventions
- 0.5 mg ranibizumab
- Drug
- Lead sponsor
- Charles C Wykoff, PhD, MD
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2017
- U.S. locations
- 4
- States / cities
- West Columbia, South Carolina • Houston, Texas • Katy, Texas + 1 more